1,171 results on '"Mosca, Marta"'
Search Results
2. A cost-of-illness study of Behçet syndrome in Italy
- Author
-
Lorenzoni, Valentina, Marinello, Diana, Palla, Ilaria, Mosca, Marta, Turchetti, Giuseppe, and Talarico, Rosaria
- Published
- 2024
- Full Text
- View/download PDF
3. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy
- Author
-
D’Alessandro, Francesco, Cazzato, Massimiliano, Laurino, Elenia, Morganti, Riccardo, Bardelli, Marco, Frediani, Bruno, Buongarzone, Claudia, Moroncini, Gianluca, Guiducci, Serena, Cometi, Laura, Benucci, Maurizio, Ligobbi, Francesca, Marotto, Daniela, and Mosca, Marta
- Published
- 2024
- Full Text
- View/download PDF
4. OMERACT systemic lupus erythematosus domain survey
- Author
-
Nielsen, Wils, Strand, Vibeke, Simon, Lee, Pinsker, Ellie, Bonilla, Dennisse, Morand, Eric, Thumboo, Julian, Aringer, Martin, Mosca, Marta, Bruce, Ian, Parodis, Ioannis, Kim, Alfred, Desai, Maya, Enman, Yvonne, Shea, Beverley, Wallace, Daniel J., Chaichian, Yashaar, Navarra, Sandra, Aranow, Cynthia, Mackay, Meggan, Trotter, Kimberly, Tayer-Shifman, Oshrat E., Duarte-García, Alí, Shan Tam, Lai, Ugarte-Gil, Manuel F., Pons-Estel, Guillermo J., Reynolds, John A., Nikpour, Mandana, Hoi, Alberta, Romero-Diaz, Juanita, Aggarwal, Amita, Mok, Chi Chiu, Fujio, Keishi, Ramsey-Goldman, Rosalind, Gladman, Dafna D., Arnaud, Laurent, Bultink, Irene E.M., Ruiz-Irastorza, Guillermo, Inês, Luís Sousa, Appenzeller, Simone, Dobrowolski, Chrisanna, Clarke, Ann Elaine, Kamen, Diane L., Barraclough, Michelle, Tani, Chiara, Gómez-Puerta, Jose A, Werth, Victoria P., Katz, Patti, Nowrouzi-Kia, Behdin, Johnson, Sindhu R., Drucker, Aaron M., and Touma, Zahi
- Published
- 2024
- Full Text
- View/download PDF
5. The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Author
-
Alberici, Federico, Antonucci, Luca, Avcin, Tadej, Bagga, Arvind, Bajema, Ingeborg M., Blasco, Miquel, Chauvet, Sophie, Cook, H. Terence, Cravedi, Paolo, Dragon-Durey, Marie-Agnès, Fischer, Lauren, Fogo, Agnes B., Frazer-Abel, Ashley, Frémeaux-Bacchi, Véronique, Görlich, Nina, Haas, Mark, Humphreys, Alister, Jha, Vivekanand, Jauhal, Arenn, Kavanagh, David, Kronbichler, Andreas, Lafayette, Richard A., Lanning, Lynne D., Lemaire, Mathieu, Le Quintrec, Moglie, Licht, Christoph, Liew, Adrian, McAdoo, Steve, Medjeral-Thomas, Nicholas R., Meroni, Pier Luigi, Morelle, Johann, Nester, Carla M., Praga, Manuel, Ramachandran, Raja, Reich, Heather N., Remuzzi, Giuseppe, Rodríguez de Córdoba, Santiago, Robinson, Gary, Ronco, Pierre, Rossing, Peter, Salant, David J., Sethi, Sanjeev, Silkjaer, Marianne, Song, Wen-chao, Spoleti, Fabrizio, Taylor, Ronald P., van de Kar, Nicole C.A.J., van Kooten, Cees, Woodward, Len, Zhang, Yuzhou, Zipfel, Peter F., Zuccato, Marco, Vivarelli, Marina, Barratt, Jonathan, Beck, Laurence H., Jr., Fakhouri, Fadi, Gale, Daniel P., Goicoechea de Jorge, Elena, Mosca, Marta, Noris, Marina, Pickering, Matthew C., Susztak, Katalin, Thurman, Joshua M., Cheung, Michael, King, Jennifer M., Jadoul, Michel, Winkelmayer, Wolfgang C., and Smith, Richard J.H.
- Published
- 2024
- Full Text
- View/download PDF
6. Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects
- Author
-
Di Battista, Marco, Tavanti, Laura, Pistelli, Francesco, Carrozzi, Laura, Da Rio, Mattia, Rossi, Alessandra, Puccetti, Lorenzo, Tavoni, Antonio, Romei, Chiara, Morganti, Riccardo, Della Rossa, Alessandra, and Mosca, Marta
- Published
- 2023
- Full Text
- View/download PDF
7. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
- Author
-
Maid, Pablo, Rillo, Oscar, Inderjeeth, Charles, Scheinecker, Clemens, Hermann, Josef, Marcolino, Flora Maria D'Andrea, Dias, Laiza H, Scafuto, Antonio, Bookman, Arthur AM, Fortin, Isabelle, Morin, Frederic, Goio, Elizabeth Jean Moreno, Pezo Ruiz, Ninette, Roman Zamoran, Carlos Patricio, Gonzalez Abarzua, Ivan Antonio, Elgueta, Sergio Fabian, Forero Illera, Elias Gonzalo, Marquez Herndez, Javier Dario, Garcia, Alex Echeverri, Pensec, Valerie Devauchelle, Hachulla, Eric, Mariette, Xavier, Gottenberg, Jacques-Eric, Le Guern, Veronique, Finzel, Stephanie, Schaefer, Valentin, Tony, Hans-Peter, Thomas Schmalzing, Marc, Tausche-Wunderlich, Anne-Kathrin, Tzioufas, Athanasios, Balog, Attila, Rojkovich, Bernadette, Varga, Tunde, Lidar, Merav, Rosner, Itzhak, Levy, Yair, Dagna, Lorenzo, Mosca, Marta, Quartuccio, Luca, Nishiyama, Susumu, Kodera, Masanari, Kaneko, Yuko, Okada, Masato, Ueki, Yukitaka, Hwan Park, Sung, van Daele, Paulus Leon Arthur, Bootsma, Hendrika, Duarte Barcelos, Filipe Alexandre, Crispim Romao, Vasco Madeira, Raimundo Vinagre, Filipe Manuel, Tavaresda Costa, Jose Antonio, Rednic, Simona, Duca, Liliana, Maslyanskiy, Alexey, Yakupova, Svetlana, Bugrova, Olga, Izmozherova, Nadezhda, Zotkin, Evgenyi, Nikolaevna Anoshenkova, Olga, Kvarnstrom, Marika, Tufan, Abdurrahman, Fisher, Benjamin, Yee, Chee Seng, Parker, Benjamin Joseph, Grader Beck, Thomas, Lawrence Ford, Theresa, Papas, Athena, Carsons, Steven, Thiagarajan, Saravanan, Zero, Domenick, McCoy, Sara, Sandorfi, Nora, Fisher, Benjamin A, Grader-Beck, Thomas, Ng, Wan-Fai, van Daele, P L A, Noaiseh, Ghaith, Elgueta, Sergio, McCoy, Sara S, Akpek, Esen, Bookman, Arthur, Sopala, Monika, Montecchi-Palmer, Michela, Luo, Wen-Lin, Scheurer, Cornelia, and Hueber, Wolfgang
- Published
- 2024
- Full Text
- View/download PDF
8. Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus
- Author
-
Ruscitti, Piero, Allanore, Yannick, Baldini, Chiara, Barilaro, Giuseppe, Bartoloni Bocci, Elena, Bearzi, Pietro, Bellis, Elisa, Berardicurti, Onorina, Biaggi, Alice, Bombardieri, Michele, Cantarini, Luca, Cantatore, Francesco Paolo, Caporali, Roberto, Caso, Francesco, Cervera, Ricard, Ciccia, Francesco, Cipriani, Paola, Chatzis, Loukas, Colafrancesco, Serena, Conti, Fabrizio, Corberi, Erika, Costa, Luisa, Currado, Damiano, Cutolo, Maurizio, D'Angelo, Salvatore, Del Galdo, Francesco, Di Cola, Ilenia, Di Donato, Stefano, Distler, Oliver, D'Onofrio, Bernardo, Doria, Andrea, Fautrel, Bruno, Fasano, Serena, Feist, Eugen, Fisher, Benjamin A., Gabini, Marco, Gandolfo, Saviana, Gatto, Mariele, Genovali, Irene, Gerli, Roberto, Grembiale, Rosa Daniela, Guggino, Giuliana, Hoffmann-Vold, Anna Maria, Iagnocco, Annamaria, Iaquinta, Francesco Salvatore, Liakouli, Vasiliki, Manoussakis, Menelaos N., Marino, Annalisa, Mauro, Daniele, Montecucco, Carlomaurizio, Mosca, Marta, Naty, Saverio, Navarini, Luca, Occhialini, Daniele, Orefice, Valeria, Perosa, Federico, Perricone, Carlo, Pilato, Andrea, Pitzalis, Costantino, Pontarini, Elena, Prete, Marcella, Priori, Roberta, Rivellese, Felice, Sarzi-Puttini, Piercarlo, Scarpa, Raffaele, Sebastiani, Giandomenico, Selmi, Carlo, Shoenfeld, Yehuda, Triolo, Giovanni, Trunfio, Francesca, Yan, Qingran, Tzioufas, Athanasios G., and Giacomelli, Roberto
- Published
- 2024
- Full Text
- View/download PDF
9. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
- Author
-
Bellomio, Veronica, Cavazzana, Ilaria, Khmelinskii, Nikita, Monticielo, Odirlei Andre, Portela Hernández, Margarita, Saavedra Salinas, Miguel Angel, Scolnik, Marina, Silva Montandon, Ana Carolina, Yilmaz, Esin, Zucchi, Dina, Bolla, Eleana, Semb, Anne Grete, Kerola, Anne M, Ikdahl, Eirik, Petri, Michelle, Pons-Estel, Guillermo J, Karpouzas, George A, Sfikakis, Petros P, Quintana, Rosana, Misra, Durga Prasanna, Borba, Eduardo Ferreira, Garcia-de la Torre, Ignacio, Popkova, Tatiana V, Artim-Esen, Bahar, Troldborg, Anne, Fragoso-Loyo, Hilda, Ajeganova, Sofia, Yazici, Ayten, Aroca-Martinez, Gustavo, Direskeneli, Haner, Ugarte-Gil, Manuel F, Mosca, Marta, Goyal, Mohit, Svenungsson, Elisabet, Macieira, Carla, Hoi, Alberta, Lerang, Karoline, Costedoat-Chalumeau, Nathalie, Tincani, Angela, Mirrakhimov, Erkin, Acosta Colman, Isabel, Danza, Alvaro, Massardo, Loreto, Blagojevic, Jelena, Yılmaz, Neslihan, Tegzová, Dana, Yavuz, Sule, Korkmaz, Cengiz, Hachulla, Eric, Moreno Alvarez, Mario J, Muñoz-Louis, Roberto, Pantazis, Nikos, and Tektonidou, Maria G
- Published
- 2024
- Full Text
- View/download PDF
10. LRP5 high bone mass (Worth-type autosomal dominant endosteal hyperostosis): case report and historical review of the literature
- Author
-
De Mattia, Giammarco, Maffi, Michele, Mosca, Marta, and Mazzantini, Maurizio
- Published
- 2023
- Full Text
- View/download PDF
11. Calcification of Joints and Arteries (CALJA) Is a Rare Cause of Arthritis and Lower Limb Ischemia: Case Report and Literature Review
- Author
-
Maffi, Michele, De Mattia, Giammarco, Mazzoni, Maria Rosa, Michelucci, Angela, Toschi, Benedetta, Adelaide, Caligo Maria, Mosca, Marta, and Mazzantini, Maurizio
- Published
- 2023
- Full Text
- View/download PDF
12. A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence
- Author
-
Bruschi, Maurizio, Angeletti, Andrea, Prunotto, Marco, Meroni, Pier Luigi, Ghiggeri, Gian Marco, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavalli, Andrea, Scapozza, Leonardo, Patel, Jigar J., Tan, John C., Lo, Ken C., Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Giannese, Domenico, Manfredi, Angelo, Ramirez, Giuseppe A., Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Bui, Federica, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisan, Isabella, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Mescia, Federica, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Ravelli, Angelo, Murtas, Corrado, Candiano, Giovanni, Caridi, Gianluca, La Porta, Edoardo, and Verrina, Enrico
- Published
- 2024
- Full Text
- View/download PDF
13. OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set
- Author
-
Nielsen, Wils, Strand, Vibeke, Simon, Lee S., Parodis, Ioannis, Kim, Alfred H.J., Desai, Maya, Enman, Yvonne, Wallace, Daniel, Chaichian, Yashaar, Navarra, Sandra, Aranow, Cynthia, MacKay, Meggan, Trotter, Kimberly, Tayer-Shifman, Oshrat E., Duarte-Garcia, Ali, Shan Tam, Lai, Ugarte-Gil, Manuel F., PonsEstel, Guillermo J., Reynolds, John A., Nikpour, Mandana, Hoi, Alberta, Romero-Diaz, Juanita, Papachristos, Danaë, Aggarwal, Amita, Mok, Chi Chiu, Fujio, Keishi, Ramsey-Goldman, Rosalind, Howe, Aaron, Kia, Behdin Nowrouzi, Bonilla, Dennisse, Thumboo, Julian, Mosca, Marta, Aringer, Martin, Johnson, Sindhu R., Drucker, Aaron M., Morand, Eric, Bruce, Ian, and Touma, Zahi
- Published
- 2024
- Full Text
- View/download PDF
14. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies
- Author
-
Ugarte-Gil, Manuel Francisco, Mak, Anselm, Leong, Joanna, Dharmadhikari, Bhushan, Kow, Nien Yee, Reátegui-Sokolova, Cristina, Elera-Fitzcarrald, Claudia, Aranow, Cinthia, Arnaud, Laurent, Askanase, Anca D, Bae, Sang-Cheol, Bernatsky, Sasha, Bruce, Ian N, Buyon, Jill, Costedoat-Chalumeau, Nathalie, Dooley, Mary Ann, Fortin, Paul R, Ginzler, Ellen M, Gladman, Dafna D, Hanly, John, Inanc, Murat, Isenberg, David, Jacobsen, Soren, James, Judith A, Jönsen, Andreas, Kalunian, Kenneth, Kamen, Diane L, Lim, Sung Sam, Morand, Eric, Mosca, Marta, Peschken, Christine, Pons-Estel, Bernardo A, Rahman, Anisur, Ramsey-Goldman, Rosalind, Reynolds, John, Romero-Diaz, Juanita, Ruiz-Irastorza, Guillermo, Sánchez-Guerrero, Jorge, Svenungsson, Elisabet, Urowitz, Murray, Vinet, Evelyne, van Vollenhoven, Ronald F, Voskuyl, Alexandre, Wallace, Daniel J, Petri, Michelle A, Manzi, Susan, Clarke, Ann Elaine, Cheung, Mike, Farewell, Vernon, and Alarcon, Graciela S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Autoimmune Disease ,Lupus ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Inflammatory and immune system ,Female ,Glucocorticoids ,Humans ,Incidence ,Longitudinal Studies ,Lupus Erythematosus ,Systemic ,Observational Studies as Topic ,Regression Analysis ,glucocorticoids ,outcome assessment ,health care ,lupus erythematosus ,systemic ,Clinical sciences ,Immunology - Abstract
In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC) exposure are known to contribute to irreversible organ damage. We aimed to examine the association between GC exposure and organ damage occurrence. We conducted a literature search (PubMed (Medline), Embase and Cochrane January 1966-October 2021). We identified original longitudinal observational studies reporting GC exposure as the proportion of users and/or GC use with dose information as well as the occurrence of new major organ damage as defined in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Meta-regression analyses were performed. Reviews, case-reports and studies with
- Published
- 2021
15. The communication GAP between patients and clinicians and the importance of patient reported outcomes in Systemic Lupus Erythematosus
- Author
-
Elefante, Elena, Cornet, Alain, Andersen, Jeanette, Somers, Amy, and Mosca, Marta
- Published
- 2023
- Full Text
- View/download PDF
16. Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study
- Author
-
Tani, Chiara, Cardelli, Chiara, Depascale, Roberto, Gamba, Anna, Iaccarino, Luca, Doria, Andrea, Bandeira, Matilde, Dinis, Sara Paiva, Romão, Vasco C., Gotelli, Emanuele, Paolino, Sabrina, Cutolo, Maurizio, Di Giosaffatte, Niccolò, Ferraris, Alessandro, Grammatico, Paola, Cavagna, Lorenzo, Codullo, Veronica, Montecucco, Carlomaurizio, Longo, Valentina, Beretta, Lorenzo, Cavazzana, Ilaria, Fredi, Micaela, Peretti, Silvia, Guiducci, Serena, Matucci-Cerinic, Marco, Bombardieri, Stefano, Burmester, Gerd R., Fonseca, João E., Frank, Charissa, Galetti, Ilaria, Hachulla, Eric, Müller-Ladner, Ulf, Schneider, Matthias, Smith, Vanessa, Tamirou, Farah, Van Laar, Jacob M., Vieira, Ana, D'Urzo, Rossella, Cannizzo, Sara, Gaglioti, Andrea, Marinello, Diana, Talarico, Rosaria, and Mosca, Marta
- Published
- 2023
- Full Text
- View/download PDF
17. Cryoglobulinemic vasculitis: a 2023 update
- Author
-
Moretti, Michele, Ferro, Francesco, Baldini, Chiara, Mosca, Marta, and Talarico, Rosaria
- Published
- 2024
- Full Text
- View/download PDF
18. Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases
- Author
-
Andreoli, Laura, Chighizola, Cecilia B., Iaccarino, Luca, Botta, Angela, Gerosa, Maria, Ramoni, Véronique, Tani, Chiara, Bermas, Bonnie, Brucato, Antonio, Buyon, Jill, Cetin, Irene, Chambers, Christina D., Clowse, Megan E.B., Costedoat-Chalumeau, Nathalie, Cutolo, Maurizio, De Carolis, Sara, Dolhain, Radboud, Fazzi, Elisa M., Förger, Frauke, Giles, Ian, Haase, Isabell, Khamashta, Munther, Levy, Roger A., Meroni, Pier Luigi, Mosca, Marta, Nelson-Piercy, Catherine, Raio, Luigi, Salmon, Jane, Villiger, Peter, Wahren-Herlenius, Marie, Wallenius, Marianne, Zanardini, Cristina, Shoenfeld, Yehuda, and Tincani, Angela
- Published
- 2023
- Full Text
- View/download PDF
19. The Role of Complement in Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Author
-
Vivarelli, Marina, primary, Barratt, Jonathan, additional, Beck, Laurence H., additional, Fakhouri, Fadi, additional, Gale, Daniel P., additional, de Jorge, Elena Goicoechea, additional, Mosca, Marta, additional, Noris, Marina, additional, Pickering, Matthew C., additional, Susztak, Katalin, additional, Thurman, Joshua M., additional, Cheung, Michael, additional, King, Jennifer M., additional, Jadoul, Michel, additional, Winkelmayer, Wolfgang C., additional, Smith, Richard J.H., additional, Alberici, Federico, additional, Antonucci, Luca, additional, Avcin, Tadej, additional, Bagga, Arvind, additional, Bajema, Ingeborg M., additional, Blasco, Miquel, additional, Chauvet, Sophie, additional, Cook, H. Terence, additional, Cravedi, Paolo, additional, Dragon-Durey, Marie-Agnès, additional, Fischer, Lauren, additional, Fogo, Agnes B., additional, Frazer-Abel, Ashley, additional, Frémeaux-Bacchi, Véronique, additional, Görlich, Nina, additional, Haas, Mark, additional, Humphreys, Alister, additional, Jha, Vivekanand, additional, Jauhal, Arenn, additional, Kavanagh, David, additional, Kronbichler, Andreas, additional, Lafayette, Richard A., additional, Lanning, Lynne D., additional, Lemaire, Mathieu, additional, Le Quintrec, Moglie, additional, Licht, Christoph, additional, Liew, Adrian, additional, McAdoo, Steve, additional, Medjeral-Thomas, Nicholas R., additional, Meroni, Pier Luigi, additional, Morelle, Johann, additional, Nester, Carla M., additional, Praga, Manuel, additional, Ramachandran, Raja, additional, Reich, Heather N., additional, Remuzzi, Giuseppe, additional, Rodríguez de Córdoba, Santiago, additional, Robinson, Gary, additional, Ronco, Pierre, additional, Rossing, Peter, additional, Salant, David J., additional, Sethi, Sanjeev, additional, Silkjaer, Marianne, additional, Song, Wen-chao, additional, Spoleti, Fabrizio, additional, Taylor, Ronald P., additional, van de Kar, Nicole C.A. J., additional, van Kooten, Cees, additional, Woodward, Len, additional, Zhang, Yuzhou, additional, Zipfel, Peter F., additional, and Zuccato, Marco, additional
- Published
- 2024
- Full Text
- View/download PDF
20. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
- Author
-
Aringer, Martin, Costenbader, Karen, Daikh, David, Brinks, Ralph, Mosca, Marta, Ramsey‐Goldman, Rosalind, Smolen, Josef S, Wofsy, David, Boumpas, Dimitrios T, Kamen, Diane L, Jayne, David, Cervera, Ricard, Costedoat‐Chalumeau, Nathalie, Diamond, Betty, Gladman, Dafna D, Hahn, Bevra, Hiepe, Falk, Jacobsen, Søren, Khanna, Dinesh, Lerstrøm, Kirsten, Massarotti, Elena, McCune, Joseph, Ruiz‐Irastorza, Guillermo, Sanchez‐Guerrero, Jorge, Schneider, Matthias, Urowitz, Murray, Bertsias, George, Hoyer, Bimba F, Leuchten, Nicolai, Tani, Chiara, Tedeschi, Sara K, Touma, Zahi, Schmajuk, Gabriela, Anic, Branimir, Assan, Florence, Chan, Tak Mao, Clarke, Ann Elaine, Crow, Mary K, Czirják, László, Doria, Andrea, Graninger, Winfried, Halda‐Kiss, Bernadett, Hasni, Sarfaraz, Izmirly, Peter M, Jung, Michelle, Kumánovics, Gábor, Mariette, Xavier, Padjen, Ivan, Pego‐Reigosa, José M, Romero‐Diaz, Juanita, Fernández, Íñigo Rúa‐Figueroa, Seror, Raphaèle, Stummvoll, Georg H, Tanaka, Yoshiya, Tektonidou, Maria G, Vasconcelos, Carlos, Vital, Edward M, Wallace, Daniel J, Yavuz, Sule, Meroni, Pier Luigi, Fritzler, Marvin J, Naden, Ray, Dörner, Thomas, and Johnson, Sindhu R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lupus ,Autoimmune Disease ,Inflammatory and immune system ,Adult ,Antibodies ,Antinuclear ,Antibodies ,Antiphospholipid ,Autoantibodies ,Cohort Studies ,Complement System Proteins ,Decision Support Techniques ,Delphi Technique ,Europe ,Female ,Humans ,International Cooperation ,Lupus Erythematosus ,Systemic ,Male ,Middle Aged ,Rheumatology ,Sensitivity and Specificity ,Societies ,Medical ,United States ,Immunology ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
ObjectiveTo develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).MethodsThis international initiative had four phases. 1) Evaluation of antinuclear antibody (ANA) as an entry criterion through systematic review and meta-regression of the literature and criteria generation through an international Delphi exercise, an early patient cohort, and a patient survey. 2) Criteria reduction by Delphi and nominal group technique exercises. 3) Criteria definition and weighting based on criterion performance and on results of a multi-criteria decision analysis. 4) Refinement of weights and threshold scores in a new derivation cohort of 1,001 subjects and validation compared with previous criteria in a new validation cohort of 1,270 subjects.ResultsThe 2019 EULAR/ACR classification criteria for SLE include positive ANA at least once as obligatory entry criterion; followed by additive weighted criteria grouped in 7 clinical (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and 3 immunologic (antiphospholipid antibodies, complement proteins, SLE-specific antibodies) domains, and weighted from 2 to 10. Patients accumulating ≥10 points are classified. In the validation cohort, the new criteria had a sensitivity of 96.1% and specificity of 93.4%, compared with 82.8% sensitivity and 93.4% specificity of the ACR 1997 and 96.7% sensitivity and 83.7% specificity of the Systemic Lupus International Collaborating Clinics 2012 criteria.ConclusionThese new classification criteria were developed using rigorous methodology with multidisciplinary and international input, and have excellent sensitivity and specificity. Use of ANA entry criterion, hierarchically clustered, and weighted criteria reflects current thinking about SLE and provides an improved foundation for SLE research.
- Published
- 2019
21. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus
- Author
-
Tedeschi, Sara K, Johnson, Sindhu R, Boumpas, Dimitrios T, Daikh, David, Dörner, Thomas, Diamond, Betty, Jacobsen, Søren, Jayne, David, Kamen, Diane L, McCune, W Joseph, Mosca, Marta, Ramsey-Goldman, Rosalind, Ruiz-Irastorza, Guillermo, Schneider, Matthias, Urowitz, Murray, Wofsy, David, Smolen, Josef S, Naden, Raymond P, Aringer, Martin, and Costenbader, Karen H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,Autoimmune Disease ,Lupus ,Consensus ,Decision Support Techniques ,Humans ,Lupus Erythematosus ,Systemic ,Reproducibility of Results ,Rheumatology ,clinical research ,methodology ,systemic lupus erythematosus ,Public Health and Health Services ,Arthritis & Rheumatology ,Clinical sciences - Abstract
European League Against Rheumatism and are jointly supporting multiphase development of systemic lupus erythematosus (SLE) classification criteria based on weighted criteria and a continuous probability scale. Prior steps included item generation, item reduction and hierarchical organisation of candidate criteria using an evidence-based approach. Our objectives were to determine relative weights using multicriteria decision analysis (MCDA) and to set a provisional threshold score for SLE classification. An SLE Expert Panel (8 European, 9 North American) submitted 164 real, unique cases with a wide range of SLE probability in a standardised format. Using the candidate criteria, experts scored and rank-ordered 20 representative cases. At an in-person meeting, experts reviewed inter-rater reliability of scoring, further refined criteria definitions and participated in an MCDA exercise. Based on expert consensus decisions on pairwise comparisons of criteria, 1000minds software calculated criteria weights and rank-ordered the remaining 144 cases based on their additive scores. The score of the lowest-ranked case for which complete expert consensus was achieved defined the provisional threshold classification score. Inter-rater reliability of scoring cases with the candidate criteria was good. MCDA involved 74 pairwise decisions and was repeated for the arthritis and mucocutaneous domains when the initial ranking of some cases did not match expert opinion. After criteria weights and additive scores were recalculated once, experts reached consensus for SLE classification for all cases scoring>83. Using an iterative process, the candidate criteria definitions were refined, preliminary weights were calculated and a provisional threshold score for SLE classification was determined.
- Published
- 2019
22. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study
- Author
-
Appenzeller, Simone, Aranow, Cynthia, Askanase, Anca, Avcin, Tadej, Bae, Sang-Cheol, Bertsias, George, Bonfa, Eloisa, Cairoli, Ernesto, Cardiel, Mario H, Cervera, Ricard, Chasset, François, Chizzolini, Carlo, Clarke, Ann E, Conti, Fabrizio, Costedoat-Chalumeau, Nathalie, Czirják, László, Doria, Andrea, Dörner, Thomas, Espinosa, Gerard, Fischer-Betz, Rebecca, Garcìa, Mercedes, Gladman, Dafna D, González, Luis A, Gunnarsson, Iva, Hamijoyo, Laniyati, Hanly, John G, Hasni, Sarfaraz A, Houssiau, Frédéric A, Inanç, Murat, Inês, Luís S, Isenberg, David, Jacobsen, Soren, Jan Wu, Yeong-Jian, Kaneko, Yuko, Katsumata, Yasuhiro, Lau, Chak S, Legge, Alexandra C, Lerang, Karoline, Limper, Maarten, Louthrenoo, Worawit, Luo, Shue-Fen, Marinho, António, Massardo, Loreto, Mathian, Alexis, Mosca, Marta, Nikpour, Mandana, Pego-Reigosa, José M, Peschken, Christine A, Pons-Estel, Bernardo A, Pons-Estel, Guillermo J, Rahman, Anisur, Rednic, Simona, Ribi, Camillo, Ruiz-Irastorza, Guillermo, Sato, Emilia I, Saxena, Amit, Schneider, Matthias, Sebastiani, Gian Domenico, Strand, Vibeke, Svenungsson, Elisabet, Tanaka, Yoshiya, Tazi Mezalek, Zoubida, Tee, Michael L, Tincani, Angela, Touma, Zahi, Troldborg, Anne, Vasconcelos, Carlos, Vinet, Évelyne, Vital, Edward M, Voskuyl, Alexandre E, Voss, Anne, Wallace, Daniel, Ward, Michael, Zamora, Leonid D, Piga, Matteo, Chessa, Elisabetta, Morand, Eric F, Ugarte-Gil, Manuel F, Tektonidou, Maria, van Vollenhoven, Ronald, Petri, Michelle, and Arnaud, Laurent
- Published
- 2022
- Full Text
- View/download PDF
23. Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals
- Author
-
Andreoli, Laura, Nalli, Cecilia, Lazzaroni, Maria Grazia, Carini, Chiara, Dall’Ara, Francesca, Reggia, Rossella, Rodrigues, Marília, Benigno, Carolina, Baldissera, Elena, Bartoloni, Elena, Basta, Fabio, Bellisai, Francesca, Bortoluzzi, Alessandra, Campochiaro, Corrado, Cantatore, Francesco Paolo, Caporali, Roberto, Ceribelli, Angela, Chighizola, Cecilia B., Conigliaro, Paola, Corrado, Addolorata, Cutolo, Maurizio, D’Angelo, Salvatore, De Stefani, Elena, Doria, Andrea, Favaro, Maria, Fischetti, Colomba, Foti, Rosario, Gabrielli, Armando, Generali, Elena, Gerli, Roberto, Gerosa, Maria, Larosa, Maddalena, Maier, Armin, Malavolta, Nazzarena, Meroni, Marianna, Meroni, Pier Luigi, Montecucco, Carlomaurizio, Mosca, Marta, Padovan, Melissa, Paolazzi, Giuseppe, Pazzola, Giulia, Peccatori, Susanna, Perricone, Roberto, Pettiti, Giorgio, Picerno, Valentina, Prevete, Immacolata, Ramoni, Véronique, Romeo, Nicoletta, Ruffatti, Amelia, Salvarani, Carlo, Sebastiani, Gian Domenico, Selmi, Carlo, Serale, Francesca, Sinigaglia, Luigi, Tani, Chiara, Trevisani, Marica, Vadacca, Marta, Valentini, Eleonora, Valesini, Guido, Visalli, Elisa, Vivaldelli, Ester, Zuliani, Lucia, and Tincani, Angela
- Published
- 2022
- Full Text
- View/download PDF
24. Definition and application of proximal-distal gradient finger perfusion in systemic sclerosis by laser speckle contrast analysis
- Author
-
Di Battista, Marco, Morganti, Riccardo, Tani, Eva, Da Rio, Mattia, Della Rossa, Alessandra, and Mosca, Marta
- Published
- 2022
- Full Text
- View/download PDF
25. Lung ultrasound and high-resolution computed tomography quantitative variations during nintedanib treatment for systemic sclerosis-associated interstitial lung disease.
- Author
-
Battista, Marco Di, Sedie, Andrea Delle, Romei, Chiara, Tavanti, Laura, Rio, Mattia Da, Morganti, Riccardo, Rossa, Alessandra Della, and Mosca, Marta
- Subjects
ANTI-inflammatory agents ,PULMONARY function tests ,VITAL capacity (Respiration) ,COMPUTED tomography ,QUESTIONNAIRES ,SEX distribution ,SMOKING ,LUNGS ,INTERSTITIAL lung diseases ,TREATMENT effectiveness ,FUNCTIONAL status ,FIBROSIS ,SYSTEMIC scleroderma ,QUALITY of life ,HEALTH outcome assessment ,EVALUATION ,DISEASE complications - Abstract
Objectives Lung ultrasound (LUS) and high-resolution CT (HRCT) are commonly used for the evaluation of interstitial lung disease (ILD). Nintedanib (NIN) is an antifibrotic therapy approved for systemic sclerosis-associated ILD (SSc-ILD). We assessed LUS and quantitative HRCT changes in SSc-ILD patients treated with NIN during a 1 year follow-up, evaluating relationships between imaging variations and functional or quality-of-life outcomes. Methods SSc-ILD patients who started NIN were enrolled and followed for 12 months. Pulmonary function tests and patient-reported outcome measures (PROMs) were assessed half-yearly and quarterly, respectively. LUS was performed quarterly evaluating the presence of B-lines (BL) and pleural line irregularities (PLI). HRCT was repeated after 1 year and quantitatively analysed with CALIPER software. Results Ten patients (70% female, mean age 62 years) were enrolled. The mean total number of both BL and PLI was constantly decreased during NIN treatment, being significantly reduced after 12 months (from 175.1 [66.7] to 120.8 [70.3] for BL, P = 0.005; and from 50.6 [32.5] to 37.2 [22.4] for PLI, P = 0.05). Male gender, smoking habit and baseline forced vital capacity <70% predicted were associated with worse LUS outcomes. A greater reduction in both BL and PLI was observed in those who improved in PROMs, especially modified Medical Research Council dyspnoea scale (P = 0.016 and P = 0.04, respectively) and Saint George's Respiratory Questionnaire (P = 0.006 and P = 0.026, respectively). No significant changes in the CALIPER percentages of normal parenchyma or ILD elements were observed after 12 months of NIN, thus paralleling the stabilization obtained at pulmonary function tests. Conclusion We present preliminary results on NIN effects on SSc-ILD as assessed by LUS, a useful method for frequently repeated monitoring, and CALIPER, a valid implementation whenever a HRCT is performed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Adapted Low-FODMAP Diet in IBS Patients with and without Fibromyalgia: Long-Term Adherence and Outcomes.
- Author
-
Lambiase, Christian, Rossi, Alessandra, Morganti, Riccardo, Cancelli, Lorenzo, Grosso, Antonio, Tedeschi, Riccardo, Rettura, Francesco, Mosca, Marta, de Bortoli, Nicola, and Bellini, Massimo
- Abstract
Background/Objectives: A low-FODMAPs Diet (LFD) is considered a "second line" dietary strategy for irritable bowel syndrome (IBS) but, after a period of strict restriction of all FODMAP foods, it has to be adapted and tailored to each patient (AdLFD). Fibromyalgia often coexists with IBS in up to 65% of cases. Our aims were to evaluate if comorbid fibromyalgia influenced the long-term clinical outcomes and adherence to an AdLFD in IBS patients. Methods: IBS patients with or without fibromyalgia who had started an AdLFD were enrolled. Patients had been evaluated before starting the LFD (T0). After a mean follow-up of 62.5 ± 22.7 months (T1), they were re-evaluated using questionnaires on disease severity, bowel habits, psychological status, and adherence to AdLFD. Results: In total, 51 IBS patients entered the study. Nineteen of them had comorbid fibromyalgia. Thirty patients reported a reduction in symptom severity at T1 in comparison with T0. Despite some slight differences in single IBS Symptom Severity Score items, comorbid fibromyalgia did not influence the IBS-SSS total score at T1. Patients with comorbid fibromyalgia showed a higher Hospital Anxiety and Depression Scale (HADS) score at baseline. A total of 44 patients showed good long-term adherence to the AdLFD. All patients improved their HADS score and had long-term adherence to the AdLFD. Conclusions: Comorbid fibromyalgia showed only a slight influence on long-term outcomes of an AdLFD on IBS symptoms, without affecting the relief of global symptoms. No influence on long-term adherence to AdLFD was detected. Hence, this approach can be taken into account in fibromyalgia patients for a nonpharmacological management of IBS symptoms. However, multicentric studies on larger samples would be welcome in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Challenges and opportunities in transitional care process in Behçet's syndrome.
- Author
-
Di Cianni, Federica, Vincenza Mastrolia, Maria, Biancalana, Edoardo, Marinello, Diana, Emmi, Giacomo, Mosca, Marta, Simonini, Gabriele, and Talarico, Rosaria
- Published
- 2024
- Full Text
- View/download PDF
28. Therapeutic strategies and outcomes in neuropsychiatric systemic lupus erythematosus: an international multicentre retrospective study.
- Author
-
Bortoluzzi, Alessandra, Fanouriakis, Antonis, Silvagni, Ettore, Appenzeller, Simone, Carli, Linda, Carrara, Greta, Cauli, Alberto, Conti, Fabrizio, Costallat, Lilian Teresa Lavras, Marchi, Ginevra De, Doria, Andrea, Fredi, Micaela, Franceschini, Franco, Garaffoni, Carlo, Hanly, John G, Mosca, Marta, Murphy, Elana, Piga, Matteo, Quartuccio, Luca, and Scirè, Carlo Alberto
- Subjects
SCALE analysis (Psychology) ,ADRENOCORTICAL hormones ,NEUROLOGIC manifestations of general diseases ,IMMUNOSUPPRESSIVE agents ,RECEIVER operating characteristic curves ,LOGISTIC regression analysis ,SYSTEMIC lupus erythematosus ,SEVERITY of illness index ,TREATMENT effectiveness ,RETROSPECTIVE studies ,MULTIVARIATE analysis ,DESCRIPTIVE statistics ,LONGITUDINAL method ,ODDS ratio ,RESEARCH ,CONFIDENCE intervals ,ALGORITHMS - Abstract
Objectives The management of neuropsychiatric systemic lupus erythematosus (NPSLE) poses considerable challenges due to limited clinical trials. Therapeutic decisions are customized based on suspected pathogenic mechanisms and symptoms severity. This study aimed to investigate therapeutic strategies and disease outcome for patients with NPSLE experiencing their first neuropsychiatric (NP) manifestation. Methods This retrospective cohort study defined NP events according to the American College of Rheumatology case definition, categorizing them into three clusters: central/diffuse, central/focal and peripheral. Clinical judgment and a validated attribution algorithm were used for NP event attribution. Data included demographic variables, SLE disease activity index, cumulative organ damage, and NP manifestation treatments. The clinical outcome of all NP events was determined by a physician seven-point Likert scale. Predictors of clinical improvement/resolution were investigated in a multivariable logistic regression analysis. Results The analysis included 350 events. Immunosuppressants and corticosteroids were more frequently initiated/escalated for SLE-attributed central diffuse or focal NP manifestations. At 12 months of follow-up, 64% of patients showed a clinical improvement in NP manifestations. Focal central events and SLE-attributed manifestations correlated with higher rates of clinical improvement. Patients with NP manifestations attributed to SLE according to clinical judgment and treated with immunosuppressants had a significantly higher probability of achieving clinical response (OR 2.55, 95%CI 1.06–6.41, P = 0.04). Age at diagnosis and focal central events emerged as additional response predictors. Conclusion NP manifestations attributed to SLE by clinical judgment and treated with immunosuppressants demonstrated improved 12-month outcomes. This underscores the importance of accurate attribution and timely diagnosis of NPSLE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy.
- Author
-
Di Battista, Marco, Rossa, Alessandra Della, and Mosca, Marta
- Published
- 2024
- Full Text
- View/download PDF
30. Evaluating the Construct of Damage in Systemic Lupus Erythematosus
- Author
-
Johnson, Sindhu R., Gladman, Dafna D., Brunner, Hermine I., Isenberg, David, Clarke, Ann E., Barber, Megan R. W., Arnaud, Laurent, Fortin, Paul R., Mosca, Marta, Voskuyl, Alexandre E., Manzi, Susan, Aranow, Cynthia, Askanase, Anca, Alarcón, Graciela S., Bae, Sang‐Cheol, Costedoat‐Chalumeau, Nathalie, English, Jessica A., Pons‐Estel, Guillermo J., Pons‐Estel, Bernardo A., Gilman, Rebecca, Ginzler, Ellen M., Hanly, John G., Jacobsen, Soren, Kalunian, Kenneth, Kamen, Diane L., Lambalgen, Chynace, Legge, Alexandra, Lim, S. Sam, Mak, Anselm, Morand, Eric F., Peschken, Christine A., Petri, Michelle, Rahman, Anisur, Ramsey‐Goldman, Rosalind, Reynolds, John A., Romero‐Diaz, Juanita, Ruiz‐Irastorza, Guillermo, Sanchez‐Guerrero, Jorge, Svenungsson, Elisabet, Touma, Zahi, Urowitz, Murray, Vinet, Evelyne, van Vollenhoven, Ronald F., Waldhauser, Heather, Wallace, Daniel J., Zoma, Asad, and Bruce, Ian N.
- Published
- 2023
- Full Text
- View/download PDF
31. Differentiating between UCTD and early-stage SLE: from definitions to clinical approach
- Author
-
Sciascia, Savino, Roccatello, Dario, Radin, Massimo, Parodis, Ioannis, Yazdany, Jinoos, Pons-Estel, Guillermo, and Mosca, Marta
- Published
- 2022
- Full Text
- View/download PDF
32. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration
- Author
-
Tedeschi, Sara K, Johnson, Sindhu R, Boumpas, Dimitrios, Daikh, David, Dörner, Thomas, Jayne, David, Kamen, Diane, Lerstrøm, Kirsten, Mosca, Marta, Ramsey‐Goldman, Rosalind, Sinnette, Corine, Wofsy, David, Smolen, Josef S, Naden, Raymond P, Aringer, Martin, and Costenbader, Karen H
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Lupus ,Autoimmune Disease ,Inflammatory and immune system ,Antibodies ,Antinuclear ,Biomarkers ,Complement System Proteins ,Consensus ,Delphi Technique ,Europe ,Humans ,International Cooperation ,Lupus Erythematosus ,Systemic ,Predictive Value of Tests ,Prognosis ,Reproducibility of Results ,Severity of Illness Index ,Terminology as Topic ,United States ,Clinical Sciences ,Public Health and Health Services ,Psychology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveTo define candidate criteria within multiphase development of systemic lupus erythematosus (SLE) classification criteria, jointly supported by the American College of Rheumatology and the European League Against Rheumatism. Prior steps included item generation and reduction by Delphi exercise, further narrowed to 21 items in a nominal group technique exercise. Our objectives were to apply an evidence-based approach to the 21 candidate criteria, and to develop hierarchical organization of criteria within domains.MethodsA literature review identified the sensitivity and specificity of the 21 candidate criteria. Data on the performance of antinuclear antibody (ANA) as an entry criterion and operating characteristics of the candidate criteria in early SLE patients were evaluated. Candidate criteria were hierarchically organized into clinical and immunologic domains, and definitions were refined in an iterative process.ResultsBased on the data, consensus was reached to use a positive ANA of ≥1:80 titer (HEp-2 cells immunofluorescence) as an entry criterion and to have 7 clinical and 3 immunologic domains, with hierarchical organization of criteria within domains. Definitions of the candidate criteria were specified.ConclusionUsing a data-driven process, consensus was reached on new, refined criteria definitions and organization based on operating characteristics. This work will be followed by a multicriteria decision analysis exercise to weight criteria and to identify a threshold score for classification on a continuous probability scale.
- Published
- 2018
33. Environment and systemic lupus erythematosus
- Author
-
Cardelli, Chiara, primary, Zucchi, Dina, additional, Elefante, Elena, additional, Signorini, Viola, additional, Menchini, Marina, additional, Stagnaro, Chiara, additional, Mosca, Marta, additional, and Tani, Chiara, additional
- Published
- 2024
- Full Text
- View/download PDF
34. The impact of environmental factors on aetiopathogenesis and clinical manifestations of Behçet's syndrome
- Author
-
Di Cianni, Federica, primary, Sulis, Antonello, additional, Italiano, Nazzareno, additional, Moretti, Michele, additional, Urban, Maria Letizia, additional, Ferro, Francesco, additional, Emmi, Giacomo, additional, Cutolo, Maurizio, additional, Mosca, Marta, additional, and Talarico, Rosaria, additional
- Published
- 2024
- Full Text
- View/download PDF
35. Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?
- Author
-
Tani, Chiara, primary, Zucchi, Dina, additional, Cardelli, Chiara, additional, Elefante, Elena, additional, Signorini, Viola, additional, Schilirò, Davide, additional, Cascarano, Giancarlo, additional, Gualtieri, Luca, additional, Valevich, Anastasiya, additional, Puccetti, Giulia, additional, Carli, Linda, additional, Stagnaro, Chiara, additional, and Mosca, Marta, additional
- Published
- 2024
- Full Text
- View/download PDF
36. Disease evolution and organ damage accrual in patients with stable UCTD: a long-term monocentric inception cohort
- Author
-
Tani, Chiara, primary, Trentin, Francesca, additional, Parma, Alice, additional, Zucchi, Dina, additional, Cardelli, Chiara, additional, Stagnaro, Chiara, additional, Elefante, Elena, additional, Signorini, Viola, additional, Carli, Linda, additional, Manca, Maria Laura, additional, and Mosca, Marta, additional
- Published
- 2024
- Full Text
- View/download PDF
37. O3 Physician experience influences glucocorticoid prescribing patterns in systemic lupus erythematosus (SLE): results from the LUPHPOS survey
- Author
-
Santos, Cristiana Sieiro, primary, Dyball, Sarah, additional, Chandwar, Kunal, additional, Chessa, Elisabetta, additional, and Mosca, Marta, additional
- Published
- 2024
- Full Text
- View/download PDF
38. P114 Steroid-free remission in systemic lupus erythematosus – Is it an achievable goal and is it sustained over time? A real-life experience from a monocentric cohort
- Author
-
Zucchi, Dina, primary, Cardelli, Chiara, additional, Trentin, Francesca, additional, Signorini, Viola, additional, Stagnaro, Chiara, additional, Carli, Linda, additional, Ferro, Francesco, additional, Elefante, Elena, additional, Schilirò, Davide, additional, Maffi, Michele, additional, Cascarano, Giancarlo, additional, Gualtieri, Luca, additional, Valevich, Anastasiya, additional, Tani, Chiara, additional, and Mosca, Marta, additional
- Published
- 2024
- Full Text
- View/download PDF
39. O25 Lupus podocytopathy: a rare form of lupus nephritis – an Italian retrospective multicenter study
- Author
-
Bonelli, Grazia Dea, primary, Sciascia, Savino, additional, Calatroni, Marta, additional, L’imperio, Vincenzo, additional, Reggiani, Francesco, additional, Fenoglio, Roberta, additional, Argolini, Lorenza, additional, Carrara, Camillo, additional, Lepori, Nicola, additional, Catapano, Fausta, additional, Gatto, Mariele, additional, Tani, Chiara, additional, Santoro, Domenico, additional, Gerosa, Maria, additional, Mosca, Marta, additional, Roccatello, Dario, additional, Sinico, Renato Alberto, additional, and Moroni, Gabriella, additional
- Published
- 2024
- Full Text
- View/download PDF
40. The communication GAP between patients and clinicians and the importance of patient reported outcomes in Systemic Lupus Erythematosus
- Author
-
Elefante, Elena, primary, Cornet, Alain, additional, Andersen, Jeanette, additional, Somers, Amy, additional, and Mosca, Marta, additional
- Published
- 2024
- Full Text
- View/download PDF
41. P122 Skin disease burden in systemic lupus erythematosus: data from a monocentric cohort
- Author
-
Cardelli, Chiara, primary, Elefante, Elena, additional, Signorini, Viola, additional, Zucchi, Dina, additional, Trentin, Francesca, additional, Cascarano, Giancarlo, additional, Gualtieri, Luca, additional, Valevich, Anastasiya, additional, Maffi, Michele, additional, Schilirò, Davide, additional, Ferro, Francesco, additional, Carli, Linda, additional, Stagnaro, Chiara, additional, Tani, Chiara, additional, and Mosca, Marta, additional
- Published
- 2024
- Full Text
- View/download PDF
42. Reproductive Health in RA, Lupus, and APS
- Author
-
Zucchi, Dina, Tani, Chiara, and Mosca, Marta
- Abstract
Systemic lupus erythematosus, antiphospholipid syndrome, and rheumatoid arthritis are chronic autoimmune diseases affecting women of childbearing age. These diseases may impair fertility and fecundity, as well as complicate pregnancy and the puerperium in these patients including disease flare and obstetric complications on both the maternal and fetal side. For each patient, an appropriate preconceptional counseling with risk stratification is required, including assessment of disease activity, organ involvement, serological profile, and comorbidities.In cases of pregnancy, the aims of treatment are to prevent disease activity, to treat disease activity in cases of flare, and to prevent maternal and fetal complications such as preeclampsia or fetal loss. In all patients with these diseases, close clinical monitoring during pregnancy and puerperium is mandatory. This review aims to summarize the fertility issues in patients with systemic lupus erythematosus, antiphospholipid syndrome, and rheumatoid arthritis and to provide an update on pregnancy management and outcomes in these patients.
- Published
- 2024
- Full Text
- View/download PDF
43. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospective Italian P-RHEUM.it study
- Author
-
Andreoli, L, Gerardi, M, Gerosa, M, Rozza, D, Crisafulli, F, Erra, R, Lini, D, Trespidi, L, Padovan, M, Ruffilli, F, Serale, F, Cuomo, G, Raffeiner, B, Semeraro, P, Tani, C, Chimenti, M, Conigliaro, P, Hoxha, A, Nalli, C, Fredi, M, Lazzaroni, M, Filippini, M, Taglietti, M, Franceschini, F, Zatti, S, Loardi, C, Orabona, R, Ramazzotto, F, Zanardini, C, Fontana, G, Gozzoli, G, Barison, C, Bizioli, P, Caporali, R, Carrea, G, Ossola, M, Maranini, B, Silvagni, E, Govoni, M, Morano, D, Verteramo, R, Doria, A, Del Ross, T, Favaro, M, Calligaro, A, Tonello, M, Larosa, M, Zen, M, Zambon, A, Mosca, M, Zucchi, D, Elefante, E, Gori, S, Iannone, F, Anelli, M, Lavista, M, Abbruzzese, A, Fasano, C, D'Angelo, S, Cutro, M, Picerno, V, Carbone, T, Padula, A, Rovere-Querini, P, Canti, V, De Lorenzo, R, Cavallo, L, Ramoni, V, Montecucco, C, Codullo, V, Milanesi, A, Pazzola, G, Comitini, G, Marvisi, C, Salvarani, C, Epis, O, Benedetti, S, Di Raimondo, G, Gagliardi, C, Lomater, C, Crepaldi, G, Bellis, E, Bellisai, F, Garcia Gonzalez, E, Pata, A, Zerbinati, M, Urban, M, Mattioli, I, Iuliano, A, Sebastiani, G, Brucato, A, Bizzi, E, Cutolo, M, Santo, L, Tonetta, S, Landolfi, G, Carrara, G, Bortoluzzi, A, Scirè, C, Tincani, A, Andreoli, Laura, Gerardi, Maria Chiara, Gerosa, Maria, Rozza, Davide, Crisafulli, Francesca, Erra, Roberta, Lini, Daniele, Trespidi, Laura, Padovan, Melissa, Ruffilli, Francesca, Serale, Francesca, Cuomo, Giovanna, Raffeiner, Bernd, Semeraro, Paolo, Tani, Chiara, Chimenti, Maria Sole, Conigliaro, Paola, Hoxha, Ariela, Nalli, Cecilia, Fredi, Micaela, Lazzaroni, Maria Grazia, Filippini, Matteo, Taglietti, Marco, Franceschini, Franco, Zatti, Sonia, Loardi, Chiara, Orabona, Rossana, Ramazzotto, Francesca, Zanardini, Cristina, Fontana, Giulia, Gozzoli, Giorgia, Barison, Claudia, Bizioli, Paola, Caporali, Roberto Felice, Carrea, Giulia, Ossola, Manuela Wally, Maranini, Beatrice, Silvagni, Ettore, Govoni, Marcello, Morano, Danila, Verteramo, Rosita, Doria, Andrea, Del Ross, Teresa, Favaro, Maria, Calligaro, Antonia, Tonello, Marta, Larosa, Maddalena, Zen, Margherita, Zambon, Alessandra, Mosca, Marta, Zucchi, Dina, Elefante, Elena, Gori, Sabrina, Iannone, Florenzo, Anelli, Maria Grazia, Lavista, Marlea, Abbruzzese, Anna, Fasano, Carlo Giuseppe, D'Angelo, Salvatore, Cutro, Maria Stefania, Picerno, Valentina, Carbone, Teresa, Padula, Angela Anna, Rovere-Querini, Patrizia, Canti, Valentina, De Lorenzo, Rebecca, Cavallo, Ludovica, Ramoni, Véronique, Montecucco, Carlomaurizio, Codullo, Veronica, Milanesi, Alessandra, Pazzola, Giulia, Comitini, Giuseppina, Marvisi, Chiara, Salvarani, Carlo, Epis, Oscar Massimiliano, Benedetti, Sara, Di Raimondo, Giuseppina, Gagliardi, Clizia, Lomater, Claudia, Crepaldi, Gloria, Bellis, Elisa, Bellisai, Francesca, Garcia Gonzalez, Estrella, Pata, Anna Paola, Zerbinati, Martina, Urban, Maria Letizia, Mattioli, Irene, Iuliano, Annamaria, Sebastiani, Giandomenico, Brucato, Antonio Luca, Bizzi, Emanuele, Cutolo, Maurizio, Santo, Leonardo, Tonetta, Sara, Landolfi, Gianpiero, Carrara, Greta, Bortoluzzi, Alessandra, Scirè, Carlo Alberto, Tincani, Angela, Andreoli, L, Gerardi, M, Gerosa, M, Rozza, D, Crisafulli, F, Erra, R, Lini, D, Trespidi, L, Padovan, M, Ruffilli, F, Serale, F, Cuomo, G, Raffeiner, B, Semeraro, P, Tani, C, Chimenti, M, Conigliaro, P, Hoxha, A, Nalli, C, Fredi, M, Lazzaroni, M, Filippini, M, Taglietti, M, Franceschini, F, Zatti, S, Loardi, C, Orabona, R, Ramazzotto, F, Zanardini, C, Fontana, G, Gozzoli, G, Barison, C, Bizioli, P, Caporali, R, Carrea, G, Ossola, M, Maranini, B, Silvagni, E, Govoni, M, Morano, D, Verteramo, R, Doria, A, Del Ross, T, Favaro, M, Calligaro, A, Tonello, M, Larosa, M, Zen, M, Zambon, A, Mosca, M, Zucchi, D, Elefante, E, Gori, S, Iannone, F, Anelli, M, Lavista, M, Abbruzzese, A, Fasano, C, D'Angelo, S, Cutro, M, Picerno, V, Carbone, T, Padula, A, Rovere-Querini, P, Canti, V, De Lorenzo, R, Cavallo, L, Ramoni, V, Montecucco, C, Codullo, V, Milanesi, A, Pazzola, G, Comitini, G, Marvisi, C, Salvarani, C, Epis, O, Benedetti, S, Di Raimondo, G, Gagliardi, C, Lomater, C, Crepaldi, G, Bellis, E, Bellisai, F, Garcia Gonzalez, E, Pata, A, Zerbinati, M, Urban, M, Mattioli, I, Iuliano, A, Sebastiani, G, Brucato, A, Bizzi, E, Cutolo, M, Santo, L, Tonetta, S, Landolfi, G, Carrara, G, Bortoluzzi, A, Scirè, C, Tincani, A, Andreoli, Laura, Gerardi, Maria Chiara, Gerosa, Maria, Rozza, Davide, Crisafulli, Francesca, Erra, Roberta, Lini, Daniele, Trespidi, Laura, Padovan, Melissa, Ruffilli, Francesca, Serale, Francesca, Cuomo, Giovanna, Raffeiner, Bernd, Semeraro, Paolo, Tani, Chiara, Chimenti, Maria Sole, Conigliaro, Paola, Hoxha, Ariela, Nalli, Cecilia, Fredi, Micaela, Lazzaroni, Maria Grazia, Filippini, Matteo, Taglietti, Marco, Franceschini, Franco, Zatti, Sonia, Loardi, Chiara, Orabona, Rossana, Ramazzotto, Francesca, Zanardini, Cristina, Fontana, Giulia, Gozzoli, Giorgia, Barison, Claudia, Bizioli, Paola, Caporali, Roberto Felice, Carrea, Giulia, Ossola, Manuela Wally, Maranini, Beatrice, Silvagni, Ettore, Govoni, Marcello, Morano, Danila, Verteramo, Rosita, Doria, Andrea, Del Ross, Teresa, Favaro, Maria, Calligaro, Antonia, Tonello, Marta, Larosa, Maddalena, Zen, Margherita, Zambon, Alessandra, Mosca, Marta, Zucchi, Dina, Elefante, Elena, Gori, Sabrina, Iannone, Florenzo, Anelli, Maria Grazia, Lavista, Marlea, Abbruzzese, Anna, Fasano, Carlo Giuseppe, D'Angelo, Salvatore, Cutro, Maria Stefania, Picerno, Valentina, Carbone, Teresa, Padula, Angela Anna, Rovere-Querini, Patrizia, Canti, Valentina, De Lorenzo, Rebecca, Cavallo, Ludovica, Ramoni, Véronique, Montecucco, Carlomaurizio, Codullo, Veronica, Milanesi, Alessandra, Pazzola, Giulia, Comitini, Giuseppina, Marvisi, Chiara, Salvarani, Carlo, Epis, Oscar Massimiliano, Benedetti, Sara, Di Raimondo, Giuseppina, Gagliardi, Clizia, Lomater, Claudia, Crepaldi, Gloria, Bellis, Elisa, Bellisai, Francesca, Garcia Gonzalez, Estrella, Pata, Anna Paola, Zerbinati, Martina, Urban, Maria Letizia, Mattioli, Irene, Iuliano, Annamaria, Sebastiani, Giandomenico, Brucato, Antonio Luca, Bizzi, Emanuele, Cutolo, Maurizio, Santo, Leonardo, Tonetta, Sara, Landolfi, Gianpiero, Carrara, Greta, Bortoluzzi, Alessandra, Scirè, Carlo Alberto, and Tincani, Angela
- Abstract
Objectives To investigate pregnancy outcomes in women with autoimmune rheumatic diseases (ARD) in the Italian prospective cohort study P-RHEUM.it. Methods Pregnant women with different ARD were enrolled for up to 20 gestational weeks in 29 Rheumatology Centres for 5 years (2018-2023). Maternal and infant information were collected in a web-based database. Results We analysed 866 pregnancies in 851 patients (systemic lupus erythematosus was the most represented disease, 19.6%). Maternal disease flares were observed in 135 (15.6%) pregnancies. 53 (6.1%) pregnancies were induced by assisted reproduction techniques, 61 (7%) ended in miscarriage and 11 (1.3%) underwent elective termination. Obstetrical complications occurred in 261 (30.1%) pregnancies, including 2.3% pre-eclampsia. Two cases of congenital heart block were observed out of 157 pregnancies (1.3%) with anti-Ro/SSA. Regarding treatments, 244 (28.2%) pregnancies were treated with glucocorticoids, 388 (44.8%) with hydroxychloroquine, 85 (9.8%) with conventional synthetic disease-modifying anti-rheumatic drugs and 122 (14.1%) with biological disease-modifying anti-rheumatic drugs. Live births were 794 (91.7%), mostly at term (84.9%); four perinatal deaths (0.5%) occurred. Among 790 newborns, 31 (3.9%) were small-for-gestational-age and 169 (21.4%) had perinatal complications. Exclusive maternal breast feeding was received by 404 (46.7%) neonates. The Edinburgh Postnatal Depression Scale was compiled by 414 women (52.4%); 89 (21.5%) scored positive for emotional distress. Conclusions Multiple factors including preconception counselling and treat-to-target with pregnancy-compatible medications may have contributed to mitigate disease-related risk factors, yielding limited disease flares, good pregnancy outcomes and frequency of complications which were similar to the Italian general obstetric population. Disease-specific issues need to be further addressed to plan preventative measures.
- Published
- 2024
44. EULAR recommendations for the management of systemic lupus erythematosus : 2023 update
- Author
-
Fanouriakis, Antonis, Kostopoulou, Myrto, Andersen, Jeanette, Aringer, Martin, Arnaud, Laurent, Bae, Sang-Cheol, Boletis, John, Bruce, Ian N., Cervera, Ricard, Doria, Andrea, Dörner, Thomas, Furie, Richard A., Gladman, Dafna D., Houssiau, Frederic A., Inês, Luís Sousa, Jayne, David, Kouloumas, Marios, Kovács, László, Mok, Chi Chiu, Morand, Eric F., Moroni, Gabriella, Mosca, Marta, Mucke, Johanna, Mukhtyar, Chetan B., Nagy, György, Navarra, Sandra, Parodis, Ioannis, Pego-Reigosa, José M., Petri, Michelle, Pons-Estel, Bernardo A., Schneider, Matthias, Smolen, Josef S., Svenungsson, Elisabet, Tanaka, Yoshiya, Tektonidou, Maria G., Teng, Yk Onno, Tincani, Angela, Vital, Edward M., van Vollenhoven, Ronald F., Wincup, Chris, Bertsias, George, Boumpas, Dimitrios T., Fanouriakis, Antonis, Kostopoulou, Myrto, Andersen, Jeanette, Aringer, Martin, Arnaud, Laurent, Bae, Sang-Cheol, Boletis, John, Bruce, Ian N., Cervera, Ricard, Doria, Andrea, Dörner, Thomas, Furie, Richard A., Gladman, Dafna D., Houssiau, Frederic A., Inês, Luís Sousa, Jayne, David, Kouloumas, Marios, Kovács, László, Mok, Chi Chiu, Morand, Eric F., Moroni, Gabriella, Mosca, Marta, Mucke, Johanna, Mukhtyar, Chetan B., Nagy, György, Navarra, Sandra, Parodis, Ioannis, Pego-Reigosa, José M., Petri, Michelle, Pons-Estel, Bernardo A., Schneider, Matthias, Smolen, Josef S., Svenungsson, Elisabet, Tanaka, Yoshiya, Tektonidou, Maria G., Teng, Yk Onno, Tincani, Angela, Vital, Edward M., van Vollenhoven, Ronald F., Wincup, Chris, Bertsias, George, and Boumpas, Dimitrios T.
- Abstract
OBJECTIVES: To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. METHODS: An international Task Force formed the questions for the systematic literature reviews (January 2018-December 2022), followed by formulation and finalisation of the statements after a series of meetings. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned, and participants finally provided their level of agreement with each item. RESULTS: The Task Force agreed on 5 overarching principles and 13 recommendations, concerning the use of hydroxychloroquine (HCQ), glucocorticoids (GC), immunosuppressive drugs (ISDs) (including methotrexate, mycophenolate, azathioprine, cyclophosphamide (CYC)), calcineurin inhibitors (CNIs, cyclosporine, tacrolimus, voclosporin) and biologics (belimumab, anifrolumab, rituximab). Advice is also provided on treatment strategies and targets of therapy, assessment of response, combination and sequential therapies, and tapering of therapy. HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. GC are used as 'bridging therapy' during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and, when possible, withdrawn. Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered. Upd
- Published
- 2024
- Full Text
- View/download PDF
45. Evaluation of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies Through Semiquantitative and Quantitative Analysis of Lung Computed Tomography
- Author
-
Roncella, Claudia, Barsotti, Simone, Valentini, Adele, Cavagna, Lorenzo, Castellana, Roberto, Cioffi, Elisa, Tripoli, Alessandra, Zanframundo, Giovanni, Biglia, Alessandro, Bartholmai, Brian, De Liperi, Annalisa, Mosca, Marta, and Romei, Chiara
- Published
- 2022
- Full Text
- View/download PDF
46. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up
- Author
-
Argolini, Lorenza Maria, Frontini, Giulia, Elefante, Elena, Saccon, Francesca, Binda, Valentina, Tani, Chiara, Scotti, Isabella, Carli, Linda, Gatto, Mariele, Esposito, Ciro, Gerosa, Maria, Caporali, Roberto, Doria, Andrea, Messa, Piergiorgio, Mosca, Marta, and Moroni, Gabriella
- Published
- 2021
- Full Text
- View/download PDF
47. The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET
- Author
-
Talarico, Rosaria, Aguilera, Silvia, Alexander, Tobias, Amoura, Zahir, Antunes, Ana M., Arnaud, Laurent, Avcin, Tadej, Beretta, Lorenzo, Bombardieri, Stefano, Burmester, Gerd R., Cannizzo, Sara, Cavagna, Lorenzo, Chaigne, Benjamin, Cornet, Alain, Costedoat-Chalumeau, Nathalie, Doria, Andrea, Ferraris, Alessandro, Fischer-Betz, Rebecca, Fonseca, João E., Frank, Charissa, Gaglioti, Andrea, Galetti, Ilaria, Grunert, Jürgen, Guimarães, Vera, Hachulla, Eric, Houssiau, Frederic, Iaccarino, Luca, Krieg, Thomas, Limper, Marteen, Malfait, Fransiska, Mariette, Xavier, Marinello, Diana, Martin, Thierry, Matthews, Lisa, Matucci-Cerinic, Marco, Meyer, Alain, Montecucco, Carlomaurizio, Mouthon, Luc, Müller-Ladner, Ulf, Rednic, Simona, Romão, Vasco C., Schneider, Matthias, Smith, Vanessa, Sulli, Alberto, Tamirou, Farah, Taruscio, Domenica, Taulaigo, Anna V., Terol, Enrique, Tincani, Angela, Ticciati, Simone, Turchetti, Giuseppe, van Hagen, P. Martin, van Laar, Jacob M., Vieira, Ana, de Vries-Bouwstra, Jeska K., Cutolo, Maurizio, and Mosca, Marta
- Published
- 2021
- Full Text
- View/download PDF
48. Interstitial Lung Disease Phenotypes and Predictive Risk Factors in Primary Sjögren's Syndrome.
- Author
-
La Rocca, Gaetano, Ferro, Francesco, Sambataro, Gianluca, Elefante, Elena, Fulvio, Giovanni, Navarro, Inmaculada Concepción, Moretti, Michele, Romei, Chiara, Mosca, Marta, and Baldini, Chiara
- Subjects
SJOGREN'S syndrome ,RAYNAUD'S disease ,INTERSTITIAL lung diseases ,RHEUMATOID factor ,UNIVARIATE analysis - Abstract
Background/Objectives: The prevalence of Interstitial Lung Disease (ILD) and risk factors for its development in patients with primary Sjögren's syndrome (pSS) are still debated, possibly due to the existence of heterogeneous pSS-related ILD phenotypes. The aims of this study were: 1. To investigate the prevalence and predictive factors for ILD development in a single-center pSS cohort; 2. To characterize different pSS-ILD phenotypes. Methods: Clinical, laboratory and imaging data of pSS patients attending our center from January 2019 to September 2023 were retrospectively analyzed. ILD presence was confirmed on HRCT. Results: Forty-three out of 474 enrolled pSS patients presented ILD (M:F = 6:37), accounting for an overall ILD prevalence of 9.1%. In 19 cases, ILD was the first manifestation of pSS (ILD-onset), while in 24 ILD was diagnosed after pSS (ILD-incident). Compared to ILD-onset, ILD-incident patients more often presented pSS-related hematologic abnormalities (p = 0.012), cutaneous involvement (p = 0.027), inflammatory arthralgias (p = 0.026), C4 hypocomplementemia (p = 0.012) and positive RF (p = 0.031). On the other hand, ILD-onset patients were significantly older at pSS diagnosis (p = 0.008) and presented more severe fibrosis on HRCT (p = 0.008). On the univariate analysis, higher ESSDAI (p = 0.011), Raynaud's phenomenon (p = 0.009), anti-Ro52 (p = 0.031), hypergammaglobulinemia (p = 0.011), Rheumatoid Factor (RF) (p = 0.038) and C4 hypocomplementemia (p = 0.044) at baseline were associated to ILD development during follow-up. On the multivariate analysis, the ESSDAI at baseline (p = 0.05) and Raynaud's phenomenon (p = 0.013) at baseline were the only independent predictors of ILD development. Conclusions: ILD is a relatively common and clinically heterogenous pSS manifestation. Elevated disease activity at pSS onset is a risk factor for ILD development, prompting careful follow-up and intriguingly suggesting that immunomodulatory therapies may prevent ILD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Challenges and opportunities in access to care for systemic lupus erythematosus patients across Europe and worldwide.
- Author
-
Mosca, Marta, Bruce, Ian N, Andersen, Jeanette, Ugarte-Gil, Manuel F, and Arnaud, Laurent
- Subjects
- *
HEALTH services accessibility , *MEDICAL quality control , *SYSTEMIC lupus erythematosus , *WORLD health , *QUALITY assurance - Abstract
SLE presents significant challenges for patients and health-care professionals (HCPs), both across Europe and worldwide. Improving health-care outcomes for patients with SLE requires a comprehensive understanding of patient disease pathways. In particular, the geographical distance between SLE patients and specialized care centres, combined with the scarcity of rheumatologists, exacerbates delays in diagnosis and management. Also, the initial SLE symptoms can often be non-specific, and providing guidelines for primary HCPs and other non-specialists is extremely important. Improvement in access to treatment is also important, with several recently approved therapies for SLE not being available in several European countries and many low- and middle-income countries (LMICs). Furthermore, in the LMICs in which these treatments are available, they are not always covered by the health-care system, making their access almost impossible for those of lower socio-economic status. A number of provisions are already in place within the European Union, to improve access to care for patients with rare and complex diseases, including those with SLE. In particular, European Reference Networks (ERNs), such the ERN for Autoimmune Diseases ReCONNET, are virtual networks involving HCPs across Europe with the aim of improving the care of patients with rare and complex diseases that require highly specialized treatment and a concentration of knowledge and resources. In addition, lupus patient organizations such as Lupus Europe play a crucial role in raising awareness of SLE and advocating for improved access to care. Together, we can work towards a future where all people living with lupus receive the comprehensive and timely care they deserve. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Baricitinib and Pulse Steroids Combination Treatment in Hyperinflammatory COVID-19: A Rheumatological Approach in the Intensive Care Unit.
- Author
-
Ferro, Francesco, La Rocca, Gaetano, Elefante, Elena, Italiano, Nazzareno, Moretti, Michele, Talarico, Rosaria, Pelati, Erika, Valentini, Katia, Baldini, Chiara, Mozzo, Roberto, De Simone, Luigi, and Mosca, Marta
- Subjects
INTENSIVE care units ,COVID-19 treatment ,BARICITINIB ,COVID-19 ,INTERSTITIAL lung diseases ,INTENSIVE care patients - Abstract
Hyperinflammatory Coronavirus disease 2019 (COVID-19) and rapidly-progressive interstitial lung diseases (RP-ILD) secondary to inflammatory myopathies (IIM) present important similarities. These data support the use of anti-rheumatic drugs for the treatment of COVID-19. The aim of this study was to compare the efficacy of combining baricitinib and pulse steroids with the Standard of Care (SoC) for the treatment of critically ill COVID-19 patients. We retrospectively enrolled consecutive patients admitted to the Intensive Care Unit (ICU) with COVID-19-pneumonia. Patients treated with SoC (dexamethasone plus remdesivir) were compared to patients treated with baricitinib plus 6-methylprednisolone pulses (Rheuma-group). We enrolled 246 patients: 104/246 in the SoC and 142/246 in the Rheuma-group. All patients presented laboratory findings suggestive of hyperinflammatory response. Sixty-four patients (26.1%) died during ICU hospitalization. The mortality rate in the Rheuma-group was significantly lower than in the SoC-group (15.5 vs. 40.4%, p < 0.001). Compared to the SoC-group, patients in the Rheuma-group presented significantly lower inflammatory biomarker levels after one week of treatment. Higher ferritin levels after one week of treatment were strongly associated with mortality (p < 0.001). In this large real-life COVID-19 cohort, baricitinib and pulse steroids led to a significant reduction in mortality, paralleled by a prompt reduction in inflammatory biomarkers. Our experience supports the similarities between hyperinflammatory COVID-19 and the IIM-associated RP-ILD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.